Expert perspectives on trial designs, study populations, safety/efficacy results, and practical implications from the 2021 ASCO (American Society of Clinical Oncology) and EHA (The European Hematology Association).
Funding from Amgen Oncology and Takeda Oncology/Content Developed Independently by OncLive
EP. 4: GIMEMA LALl2317: Sequential Chemotherapy and Blinatumomab for Adult ALL
July 8th 2021Robin Foà, MD, discusses results from the GIMEMA LAL2317 sequential chemotherapy-blinatumomab frontline trial, where experts evaluated the efficacy of blinatumomab in increasing the early MRD (minimal residual disease) negativity rate.